CA2517573A1 - Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia - Google Patents
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia Download PDFInfo
- Publication number
- CA2517573A1 CA2517573A1 CA002517573A CA2517573A CA2517573A1 CA 2517573 A1 CA2517573 A1 CA 2517573A1 CA 002517573 A CA002517573 A CA 002517573A CA 2517573 A CA2517573 A CA 2517573A CA 2517573 A1 CA2517573 A1 CA 2517573A1
- Authority
- CA
- Canada
- Prior art keywords
- alkylene
- nr6r7
- alkyl
- residue
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/28—Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin
Abstract
The present invention provides substituted azetidinone compounds of formula (1), formulations and processes for preparing the same which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols in a subject.
Claims (18)
1. A compound represented by the structural formula (I):
or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein in Formula (I) above:
X, Y and Z can be the same or different and each is independently selected from the group consisting of -CH2-, -CH(alkyl)- and -C(alkyl)2-;
Q1 and Q2 can be the same or different and each is independently selected from the group consisting of H, -(C0-C30 alkylene)-G, -OR6, -OC(O)R6, -OC(O)OR9, ~OC(O)NR6R7, and -L-M;
Q3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6,7 -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -S(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
Q4 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
Q5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR8C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
wherein optionally one or more carbon atoms of the ~(C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by ~O-, -C(O)-, -CH=CH-, -C~C-, -N(alkyl)-, -N(alkylaryl)- or ~NH-;
G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue comprising 2 to 9 amino acids, trialkylammoniumalkyl radical and ~S(O)2-OH, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with ~L-M;
L is selected from the group consisting of wherein Me is methyl;
M is selected from the group of moieties consisting of pharmaceutically acceptable salts of the moieties (M1) and (M3) to (M10) and free acids of the moieties (M1) and (M3) to (M10);
R2 and R3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;
R6, R7 and R8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and each R9 is independently alkyl, aryl or arylalkyl.
each R10 is independently H or alkyl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the seam of m, q and n is 1, 2, 3, 4 or 5;
x1 is 1 to 10;
x2 is 1 to 10;
x3 is 1 to 10;
x4 is 1 to 10;
x5 is 1 to 10;
x6 is 1 to 10;
x7 is 1 to 10;
x8 is 1 to 10;
x9 is 1 to 10;
x10 is 1 to 10;
x11 is 1 to 10;
x12 is 1 to 10;
x13 is 1 to 10;
x14 is 1 to 10;
x15 is 1 to 10; and x16 is 1 to 10;
x17 is 1 to 10; and x18 is 1 to 10;
with the proviso that at least one of Q1, Q2, Q3, Q4 and Q5 is ~L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with ~L-M.
or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein in Formula (I) above:
X, Y and Z can be the same or different and each is independently selected from the group consisting of -CH2-, -CH(alkyl)- and -C(alkyl)2-;
Q1 and Q2 can be the same or different and each is independently selected from the group consisting of H, -(C0-C30 alkylene)-G, -OR6, -OC(O)R6, -OC(O)OR9, ~OC(O)NR6R7, and -L-M;
Q3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6,7 -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -S(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
Q4 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
Q5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR8C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
wherein optionally one or more carbon atoms of the ~(C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by ~O-, -C(O)-, -CH=CH-, -C~C-, -N(alkyl)-, -N(alkylaryl)- or ~NH-;
G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue comprising 2 to 9 amino acids, trialkylammoniumalkyl radical and ~S(O)2-OH, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with ~L-M;
L is selected from the group consisting of wherein Me is methyl;
M is selected from the group of moieties consisting of pharmaceutically acceptable salts of the moieties (M1) and (M3) to (M10) and free acids of the moieties (M1) and (M3) to (M10);
R2 and R3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;
R6, R7 and R8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and each R9 is independently alkyl, aryl or arylalkyl.
each R10 is independently H or alkyl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the seam of m, q and n is 1, 2, 3, 4 or 5;
x1 is 1 to 10;
x2 is 1 to 10;
x3 is 1 to 10;
x4 is 1 to 10;
x5 is 1 to 10;
x6 is 1 to 10;
x7 is 1 to 10;
x8 is 1 to 10;
x9 is 1 to 10;
x10 is 1 to 10;
x11 is 1 to 10;
x12 is 1 to 10;
x13 is 1 to 10;
x14 is 1 to 10;
x15 is 1 to 10; and x16 is 1 to 10;
x17 is 1 to 10; and x18 is 1 to 10;
with the proviso that at least one of Q1, Q2, Q3, Q4 and Q5 is ~L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with ~L-M.
2. A compound represented by the structural formula (IA):
or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (IA), wherein in Formula (IA) above:
X, Y and Z can be the same or different and each is independently selected from the group consisting of -CH2-, -CH(alkyl)- and -C(alkyl)2-;
Q1 and Q2 can be the same or different and each is independently selected from the group consisting of H, -(C0-C30 alkylene)-G, -OR6, -OC(O)R6, -OC(O)OR9, ~OC(O)NR6R7, and ~L-M;
Q3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
Q4 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
Q5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
wherein optionally one or more carbon atoms of the ~(C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by ~O-, -C(O)-, -CH=CH-, -C~C-, -N(alkyl)-, -N(alkylaryl)- or ~NH-;
G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue comprising 2 to 9 amino acids, trialkylammoniumalkyl radical and ~S(O)2-OH, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with ~L-M;
L is selected from the group consisting of wherein Me is methyl;
M is selected from the group of moieties consisting of and pharmaceutically acceptable salts of moieties (M1) to (M33);
R2 and R3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;
R6, R7 and R8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and each R9 is independently alkyl, aryl or arylalkyl.
each R10 is independently H or alkyl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
x8 is 1 to 10;
x9 is 1 to 10;
x10 is 1 to 10;
x11 is 1 to 10;
x12 is 1 to 10;
x13 is 1 to 10;
x14 is 1 to 10;
x15 is 1 to 10; and x16 is 1 to 10;
x17 is 1 t0 10; and x15 is 1 to 10;
with the proviso that at least one of Q1, Q2, Q3, Q4 and Q5 is ~L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of C is substituted with ~L-M.
or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (IA), wherein in Formula (IA) above:
X, Y and Z can be the same or different and each is independently selected from the group consisting of -CH2-, -CH(alkyl)- and -C(alkyl)2-;
Q1 and Q2 can be the same or different and each is independently selected from the group consisting of H, -(C0-C30 alkylene)-G, -OR6, -OC(O)R6, -OC(O)OR9, ~OC(O)NR6R7, and ~L-M;
Q3 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
Q4 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
Q5 is 1 to 5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, -(C0-C30 alkylene)-G, -(C0-C10 alkylene)-OR6, -(C0-C10 alkylene)-C(O)R6, -(C0-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-OC(O)R6, -(C0-C10 alkylene)-OC(O)OR9, -CH=CH-C(O)R6, -CH=CH-C(O)OR6, -C~C-C(O)OR6, -C~C-C(O)R6, -O-(C1-C10 alkylene)-OR6, -O-(C1-C10 alkylene)-C(O)R6, -O-(C1-C10 alkylene)-C(O)OR6, -CN, -O-(C1-C10 alkylene)-C(O)NR6R7, -O-(C0-C10 alkylene)-C(O)NR6NR7C(O)OR6, -O-(C1-C10 alkylene)-C(O)(aryl)-N-N=N-, -OC(O)-(C1-C10 alkylene)-C(O)OR6, -(C0-C10 alkylene)-C(O)NR6R7, -(C0-C10 alkylene)-OC(O)NR6R7, -NO2, -(C0-C10 alkylene)-NR6R7, -O-(C2-C10 alkylene)-NR6R7, -NR6C(O)R7, -NR6C(O)OR9, -NR6C(O)NR7R8, -NR6S(O)0-2R9, -N(S(O)0-2R9)2, -CHNOR6, -C(O)NR6R7, -C(O)NR6NR6R7, -S(O)0-2NR6R7, -S(O)0-2R9, -O-C(O)-(C1-C10 alkylene)-C(O)NR6R7, -OC(O)-(C1-C10 alkylene)-NR6C(O)O-(alkylaryl), -P(O)(OR10)2, -(C1-C10 alkylene)-OSi(alkyl)3, -CF3, -OCF3, halo, alkoxyalkoxy, alkoxyalkoxyalkoxy, alkoxycarbonylalkoxy, alkoxyarylalkoxy, alkoxyiminoalkyl, alkyldioyl, allyloxy, aryl, arylalkyl, aryloxy, arylalkoxy, aroyl, aroyloxy, aroylaroyloxy, arylalkoxycarbonyl, benzoylbenzoyloxy, heteroaryl, heteroarylalkyl, heteroarylalkoxy, dioxolanyl, heterocyclyl, heterocyclylalkyl, heterocyclylcarbonyl, heterocyclylcarbonylalkoxy and ~L-M;
wherein optionally one or more carbon atoms of the ~(C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by ~O-, -C(O)-, -CH=CH-, -C~C-, -N(alkyl)-, -N(alkylaryl)- or ~NH-;
G is selected from the group consisting of a sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue, oligopeptide residue comprising 2 to 9 amino acids, trialkylammoniumalkyl radical and ~S(O)2-OH, wherein optionally the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of G is substituted with ~L-M;
L is selected from the group consisting of wherein Me is methyl;
M is selected from the group of moieties consisting of and pharmaceutically acceptable salts of moieties (M1) to (M33);
R2 and R3 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl and aryl;
R6, R7 and R8 can be the same or different and each is independently selected from the group consisting of hydrogen, alkyl, aryl and arylalkyl; and each R9 is independently alkyl, aryl or arylalkyl.
each R10 is independently H or alkyl;
q is 0 or 1;
r is 0 or 1;
m, n and p are independently selected from 0, 1, 2, 3 or 4; provided that at least one of q and r is 1, and the sum of m, n, p, q and r is 1, 2, 3, 4, 5 or 6; and provided that when p is 0 and r is 1, the sum of m, q and n is 1, 2, 3, 4 or 5;
x8 is 1 to 10;
x9 is 1 to 10;
x10 is 1 to 10;
x11 is 1 to 10;
x12 is 1 to 10;
x13 is 1 to 10;
x14 is 1 to 10;
x15 is 1 to 10; and x16 is 1 to 10;
x17 is 1 t0 10; and x15 is 1 to 10;
with the proviso that at least one of Q1, Q2, Q3, Q4 and Q5 is ~L-M or the sugar residue, disugar residue, trisugar residue, tetrasugar residue, sugar acid, amino sugar, amino acid residue or oligopeptide residue of C is substituted with ~L-M.
3. The compound according to claim 1 or 2, wherein m, n and r are each zero, q is 1, p is 2, and Z is -CH2-.
4. The compound according to claim 1 or 2, wherein m, n and r are each zero, q is 1, p is 2, and Z is -CH2-, Q1 is -OR6, wherein R6 is hydrogen and Q5 is fluorine.
5. The compound according to claim 1 or 2, wherein R2 and R3 are each preferably hydrogen.
6. The compound according to claim 1 or 2, wherein Q1 and Q2 are each independently selected from the group consisting of -OR6, -O(CO)R6, -O(CO)OR9 and -O(CO)NR6R7.
7. The compound according to claim 1 or 2, wherein Q4 is halo or -OR6.
8. The compound according to claim 1 or 2, wherein Q1 is ~OR6 wherein R6 is H.
9. The compound according to claim 1 or 2, wherein Q1, Q2, Q3, Q4 or Q5 is~L-M.
10. The compound according to claim 1 or 2, wherein Q1, Q2, Q3, Q4 or Q5 is -(C0-C30 alkylene)-G.
11. The compound according to claim 1 or 2, wherein G is selected from the group consisting of:
wherein R, R a and R b can be the same or different and each is independently selected from the group consisting of H, -OH, halo, -NH2, azido, alkoxyalkoxy or -W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31)-, -NH-C(O)-N(R31)- and -O-C(S)-N(R31)-;
R2a and R6a can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, aryl and arylalkyl;
R3a, R4a, R5a, R7a, R3b and R4b can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, arylalkyl, -C(O)alkyl and -C(O)aryl;
R30 is independently selected from the group consisting of R32-substituted T, R32-substituted-T-alkyl, R32-substituted-alkenyl, R32-substituted-alkyl, R32-substituted-cycloalkyl and R32-substituted-cycloalkylalkyl;
R31 is independently selected from the group consisting of H and alkyl;
T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is 1 to 3 substituents which are each independently selected from the group consisting of H, halo, alkyl, -OH, phenoxy, -CF3, -NO2, alkoxy, methylenedioxy, oxo, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -N(CH3)2, -C(O)-NHalkyl, -C(O)-N(alkyl)2, -C(O)-alkyl, -C(O)-alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group.
wherein R, R a and R b can be the same or different and each is independently selected from the group consisting of H, -OH, halo, -NH2, azido, alkoxyalkoxy or -W-R30;
W is independently selected from the group consisting of -NH-C(O)-, -O-C(O)-, -O-C(O)-N(R31)-, -NH-C(O)-N(R31)- and -O-C(S)-N(R31)-;
R2a and R6a can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, aryl and arylalkyl;
R3a, R4a, R5a, R7a, R3b and R4b can be the same or different and each is independently selected from the group consisting of H, alkyl, acetyl, arylalkyl, -C(O)alkyl and -C(O)aryl;
R30 is independently selected from the group consisting of R32-substituted T, R32-substituted-T-alkyl, R32-substituted-alkenyl, R32-substituted-alkyl, R32-substituted-cycloalkyl and R32-substituted-cycloalkylalkyl;
R31 is independently selected from the group consisting of H and alkyl;
T is independently selected from the group consisting of phenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzothiazolyl, thiadiazolyl, pyrazolyl, imidazolyl and pyridyl;
R32 is 1 to 3 substituents which are each independently selected from the group consisting of H, halo, alkyl, -OH, phenoxy, -CF3, -NO2, alkoxy, methylenedioxy, oxo, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, -N(CH3)2, -C(O)-NHalkyl, -C(O)-N(alkyl)2, -C(O)-alkyl, -C(O)-alkoxy and pyrrolidinylcarbonyl; or R32 is a covalent bond and R31, the nitrogen to which it is attached and R32 form a pyrrolidinyl, piperidinyl, N-methyl-piperazinyl, indolinyl or morpholinyl group, or a alkoxycarbonyl-substituted pyrrolidinyl, piperidinyl, N-methylpiperazinyl, indolinyl or morpholinyl group.
12. The compound according to claim 11, wherein G is selected from:
wherein Ac is acetyl and Ph is phenyl.
wherein Ac is acetyl and Ph is phenyl.
13. The compound according to claim 1 or 2, wherein optionally one or more carbon atoms of the ~(C0-C30 alkylene)- radical of Q1, Q2, Q3, Q4 and Q5 is independently replaced by ~O-.
14. The compound according to claim 1 or 2, which is
15. A pharmaceutical composition for the treatment or prevention of a vascular condition, diabetes, obesity, stroke, lowering a concentration of a sterol or stanol in plasma of a mammal, preventing demyelination or treating Alzheimer's disease and/or regulating levels of amyloid is .beta. peptides in a subject comprising a therapeutically effective amount of a compound of claim 1 or 2 in a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising a cholesterol-lowering effective amount of a compound of claim 1 or tin a pharmaceutically acceptable carrier.
17. A method of treating or preventing a vascular condition, diabetes, obesity, stroke, lowering a concentration of a sterol or stanol in plasma of e. mammal, preventing demyelination or treating Alzheimer's disease or regulating a level of an amyloid .beta. peptide in a subject comprising the step of administering to a subject in need of such treatment an effective amount of a compound of claim 1 or 2.
18. A method of lowering cholesterol level in plasma of a mammal in need of such treatment comprising administering a pharmaceutically effective amount of the compound of claim 1 or 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45272203P | 2003-03-07 | 2003-03-07 | |
US60/452,722 | 2003-03-07 | ||
PCT/US2004/006555 WO2004081004A1 (en) | 2003-03-07 | 2004-03-03 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2517573A1 true CA2517573A1 (en) | 2004-09-23 |
CA2517573C CA2517573C (en) | 2011-12-06 |
Family
ID=32990672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2517573A Expired - Fee Related CA2517573C (en) | 2003-03-07 | 2004-03-03 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
Country Status (7)
Country | Link |
---|---|
US (1) | US7192944B2 (en) |
EP (1) | EP1606287B1 (en) |
JP (1) | JP2006519869A (en) |
CN (1) | CN1756755A (en) |
CA (1) | CA2517573C (en) |
MX (1) | MXPA05009502A (en) |
WO (1) | WO2004081004A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176194B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
ATE418551T1 (en) * | 2003-03-07 | 2009-01-15 | Schering Corp | SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA |
US7235543B2 (en) * | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7635705B2 (en) * | 2005-06-20 | 2009-12-22 | Schering Corporation | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
MX2009002398A (en) * | 2006-09-05 | 2009-03-16 | Schering Corp | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis. |
US9212175B2 (en) | 2009-03-06 | 2015-12-15 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
MX363161B (en) | 2011-10-28 | 2019-03-13 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease. |
ES2633766T3 (en) | 2011-10-28 | 2017-09-25 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver diseases |
KR20160002773A (en) | 2013-03-15 | 2016-01-08 | 루메나 파마수티컬즈, 인코포레이티드 | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
MX2015013196A (en) | 2013-03-15 | 2016-04-15 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease. |
CA3129827A1 (en) | 2019-02-12 | 2020-08-20 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency |
Family Cites Families (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3108097A (en) | 1963-10-22 | Ehnojs | ||
US2809194A (en) | 1957-10-08 | Thiadiazine type natriuretic agents | ||
BE578515A (en) | 1958-05-07 | |||
NL127065C (en) | 1964-04-22 | |||
NL137318C (en) | 1964-06-09 | |||
US3716583A (en) | 1969-04-16 | 1973-02-13 | Sumitomo Chemical Co | Phenoxy carboxylic acid derivative |
US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2230383C3 (en) | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarboxylic acid derivatives and processes for making the same |
US4148923A (en) | 1972-05-31 | 1979-04-10 | Synthelabo | 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity |
US3948973A (en) | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US4626549A (en) | 1974-01-10 | 1986-12-02 | Eli Lilly And Company | Treatment of obesity with aryloxyphenylpropylamines |
JPS5195049A (en) | 1975-02-12 | 1976-08-20 | * **********so*****no***tsu*****************************************ni*no | |
US4235896A (en) | 1975-02-12 | 1980-11-25 | Orchimed S.A. | Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same |
US4179515A (en) | 1975-02-12 | 1979-12-18 | Orchimed S. A. | Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition |
US4075000A (en) | 1975-05-27 | 1978-02-21 | Eli Lilly And Company | Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones |
US4304718A (en) | 1975-10-06 | 1981-12-08 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
US4472309A (en) | 1975-10-06 | 1984-09-18 | Fujisawa Pharmaceutical Co., Ltd. | 2-Azetidinone compounds and processes for preparation thereof |
US4166907A (en) | 1976-11-01 | 1979-09-04 | E. R. Squibb & Sons, Inc. | 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity |
US4144232A (en) | 1976-12-23 | 1979-03-13 | Eli Lilly And Company | Substituted azetidin-2-one antibiotics |
FR2403078A1 (en) | 1977-09-19 | 1979-04-13 | Lafon Labor | NEW PROCESS FOR THE PREPARATION OF PHARMACEUTICAL, COSMETIC OR DIAGNOSIS FORMS |
IT1157365B (en) | 1977-10-24 | 1987-02-11 | Sandoz Ag | MEDICATIONS TO TREAT OBESITY OR REDUCE BODY WEIGHT |
US4250191A (en) | 1978-11-30 | 1981-02-10 | Edwards K David | Preventing renal failure |
US4375475A (en) | 1979-08-17 | 1983-03-01 | Merck & Co., Inc. | Substituted pyranone inhibitors of cholesterol synthesis |
US4260743A (en) | 1979-12-31 | 1981-04-07 | Gist-Brocades N.V. | Preparation of β-lactams and intermediates therefor |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DE3107100A1 (en) | 1981-02-20 | 1982-09-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | AZAPROSTACYCLINE, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE |
US4500456A (en) | 1981-03-09 | 1985-02-19 | Eli Lilly And Company | Preparation of 4-fluoroazetidinones using FClO3 |
US4784734A (en) | 1981-04-10 | 1988-11-15 | Otsuka Kagaku Yakuhin Kabushiki Kaisha | Azetidinone derivatives and process for the preparation of the same |
US4602005A (en) | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
US4602003A (en) | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
US4443372A (en) | 1982-06-23 | 1984-04-17 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4534786A (en) | 1982-06-23 | 1985-08-13 | Chevron Research Company | 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators |
US4595532A (en) | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
CA1256650A (en) | 1983-03-25 | 1989-06-27 | Toshinari Tamura | Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds |
US4675399A (en) | 1983-03-28 | 1987-06-23 | Notre Dame University | Cyclization process for β-lactams |
EP0126709B1 (en) | 1983-03-28 | 1991-04-03 | Ciba-Geigy Ag | Process for the preparation of optically active azetidinones |
WO1985004876A1 (en) | 1984-04-24 | 1985-11-07 | Takeda Chemical Industries, Ltd. | 2-azetidinone derivatives and process for their preparation |
US4576749A (en) | 1983-10-03 | 1986-03-18 | E. R. Squibb & Sons, Inc. | 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones |
US4680391A (en) | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5229381A (en) | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5229510A (en) | 1983-12-01 | 1993-07-20 | Merck & Co., Inc. | β-lactams useful in determining the amount of elastase in a clinical sample |
US4654362A (en) | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
FR2561916B1 (en) | 1984-03-30 | 1987-12-11 | Lafon Labor | GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION |
US4581170A (en) | 1984-08-03 | 1986-04-08 | E. R. Squibb & Sons, Inc. | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4633017A (en) | 1984-08-03 | 1986-12-30 | E. R. Squibb & Sons, Inc. | N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones |
US4576748A (en) | 1984-09-17 | 1986-03-18 | Merck & Co., Inc. | 3-Hydroxy-3-aminoethyl β-lactams |
US4620867A (en) | 1984-09-28 | 1986-11-04 | Chevron Research Company | 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides |
AR240698A1 (en) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts |
US4642903A (en) | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4680289A (en) | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
DE3787815T2 (en) | 1986-02-19 | 1994-03-24 | Sanraku Inc | Azetidinone derivatives. |
GB8607312D0 (en) | 1986-03-25 | 1986-04-30 | Ici Plc | Therapeutic agents |
FR2598146B1 (en) | 1986-04-30 | 1989-01-20 | Rech Ind | NEW PROCESS FOR THE PREPARATION OF FIBRATES. |
DE3621861A1 (en) | 1986-06-30 | 1988-01-14 | Laszlo Dr Med Ilg | USE OF ARYLOXYCARBONIC ACID DERIVATIVES AGAINST DERMATOLOGICAL DISEASES |
FR2602423B1 (en) | 1986-08-08 | 1989-05-05 | Ethypharm Sa | PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS |
US4814354A (en) | 1986-09-26 | 1989-03-21 | Warner-Lambert Company | Lipid regulating agents |
US4803266A (en) | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
PH25145A (en) | 1986-12-15 | 1991-02-19 | Laverne Dwaine Boeck | Process for producing the a10255 complex and corresponding microorganism |
US5229362A (en) | 1986-12-15 | 1993-07-20 | Eli Lilly And Company | Antibiotic A10255 complex and factors, and process and production therefor |
JPS63156788A (en) | 1986-12-22 | 1988-06-29 | Sanraku Inc | Optically active azetidinones |
US5110730A (en) | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
EP0288973B1 (en) | 1987-04-28 | 1993-01-13 | Fujisawa Astra Ltd. | Benzothiazolinone derivatives, their production and pharmaceutical composition |
US5106833A (en) | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
US5091525A (en) | 1987-10-07 | 1992-02-25 | Eli Lilly And Company | Monohydrate and DMF solvates of a new carbacephem antibiotic |
US4834846A (en) | 1987-12-07 | 1989-05-30 | Merck & Co., Inc. | Process for deblocking N-substituted β-lactams |
FR2627696B1 (en) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | NEW GALENIC FORM OF FENOFIBRATE |
DE3807895A1 (en) | 1988-03-10 | 1989-09-21 | Knoll Ag | PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER |
GB8813012D0 (en) | 1988-06-02 | 1988-07-06 | Norsk Hydro As | Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals |
US4952689A (en) | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
US5112616A (en) | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US4876365A (en) | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
US5260305A (en) | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
FR2640621B1 (en) | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-ARYL-AZETIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ELASTASE INHIBITORS |
US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
CA2016467A1 (en) | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
JPH03108490A (en) | 1989-06-30 | 1991-05-08 | Shionogi & Co Ltd | Phospholipase a2 inhibitor |
US5021461A (en) | 1989-07-26 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Method of treating diabetes mellitus with bisphenol derivatives |
US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5219574A (en) | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5223264A (en) | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5188825A (en) | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
US5298497A (en) | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5120729A (en) | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
US5120713A (en) | 1990-09-10 | 1992-06-09 | Applied Research Systems Ars Holding N.V. | Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
US5190970A (en) | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5130333A (en) | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
JP2640986B2 (en) | 1990-11-08 | 1997-08-13 | 高砂香料工業株式会社 | Process for producing (1'R, 3S) -3- (1'-hydroxyethyl) -azetidin-2-one or a derivative thereof |
AU642066B2 (en) | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5157025A (en) | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
ATE158789T1 (en) | 1991-07-23 | 1997-10-15 | Schering Corp | SUBSTITUTED BETA-LACTAM COMPOUNDS AS HYPOCHOLESTEROLEMIC AGENTS AND METHOD FOR THE PRODUCTION THEREOF |
US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
US5278176A (en) | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
EP0666846A1 (en) * | 1992-10-27 | 1995-08-16 | Merck & Co. Inc. | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
US5631363A (en) * | 1992-11-13 | 1997-05-20 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5851553A (en) * | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5976570A (en) * | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
US5554746A (en) * | 1994-05-16 | 1996-09-10 | Isis Pharmaceuticals, Inc. | Lactam nucleic acids |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
GB9421836D0 (en) * | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms of hydrophobic substances |
GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
BR9510420A (en) * | 1994-12-22 | 2004-04-20 | Smithkline Beecham Plc | Replaced Azetidin-2-ones for atherosclerosis treatment |
FR2730231B1 (en) * | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | COMBINATION OF FENOFIBRATE AND VITAMIN E, USE IN THERAPEUTICS |
US5998441A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
FR2737121B1 (en) * | 1995-07-27 | 1997-10-03 | Cl Pharma | NEW GALENIC FORMULATIONS OF FENOFIBRATE AND THEIR APPLICATIONS |
WO1997016424A1 (en) * | 1995-11-02 | 1997-05-09 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone |
MXPA98003802A (en) * | 1995-11-14 | 2005-04-29 | Abbott Gmbh & Co Kg | Stabilized thyroid hormone preparations and methods of making same. |
US5925333A (en) * | 1995-11-15 | 1999-07-20 | Massachusetts Institute Of Technology | Methods for modulation of lipid uptake |
JPH09143156A (en) * | 1995-11-17 | 1997-06-03 | Tanabe Seiyaku Co Ltd | Production of acetoxyazetidinone derivative and its synthetic intermediate |
US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
US5847008A (en) * | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
US5858409A (en) * | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
US5843984A (en) * | 1996-05-09 | 1998-12-01 | Eli Lilly And Company | Sulfated benzothiophene derivatives, methods of use and formulations containing same |
US5886171A (en) * | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US6245743B1 (en) * | 1996-06-05 | 2001-06-12 | Cor Therapeutics, Inc. | Inhibitors of factor Xa |
KR19990036207A (en) * | 1996-06-12 | 1999-05-25 | 히라타 다다시 | Lipid metabolism improver |
US5883109A (en) * | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
US5952003A (en) * | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
US6057342A (en) * | 1996-08-16 | 2000-05-02 | Dupont Pharmaceutical Co. | Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof |
US6235706B1 (en) * | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US6251852B1 (en) * | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
EP0950046B1 (en) * | 1996-09-23 | 2002-04-10 | Naeja Pharmaceutical Inc. | 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators |
FR2758459B1 (en) * | 1997-01-17 | 1999-05-07 | Pharma Pass | FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME |
US6066653A (en) * | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
US5886191A (en) * | 1997-08-18 | 1999-03-23 | Dupont Pharmaceuticals Company | Amidinoindoles, amidinoazoles, and analogs thereof |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
US6207697B1 (en) * | 1997-09-09 | 2001-03-27 | Dupont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa |
US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
WO1999050255A2 (en) * | 1998-03-27 | 1999-10-07 | Du Pont Pharmaceuticals Company | Disubstituted pyrazolines and triazolines as factor xa inhibitors |
US5919672A (en) * | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
US6248781B1 (en) * | 1998-10-21 | 2001-06-19 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US7235543B2 (en) * | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
ATE418551T1 (en) * | 2003-03-07 | 2009-01-15 | Schering Corp | SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA |
EP1868653A2 (en) * | 2005-04-12 | 2007-12-26 | PSivida Inc. | Hmgcoa reductase inhibitor codrugs and uses thereof |
-
2004
- 2004-03-03 CA CA2517573A patent/CA2517573C/en not_active Expired - Fee Related
- 2004-03-03 US US10/791,979 patent/US7192944B2/en active Active
- 2004-03-03 MX MXPA05009502A patent/MXPA05009502A/en active IP Right Grant
- 2004-03-03 WO PCT/US2004/006555 patent/WO2004081004A1/en active Application Filing
- 2004-03-03 CN CNA2004800060399A patent/CN1756755A/en active Pending
- 2004-03-03 EP EP04716968.5A patent/EP1606287B1/en not_active Expired - Lifetime
- 2004-03-03 JP JP2006509070A patent/JP2006519869A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MXPA05009502A (en) | 2005-10-18 |
JP2006519869A (en) | 2006-08-31 |
US20040180860A1 (en) | 2004-09-16 |
CA2517573C (en) | 2011-12-06 |
EP1606287B1 (en) | 2013-10-02 |
CN1756755A (en) | 2006-04-05 |
US7192944B2 (en) | 2007-03-20 |
WO2004081004A1 (en) | 2004-09-23 |
EP1606287A1 (en) | 2005-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2517572A1 (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | |
CA2517571A1 (en) | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | |
CA2517573A1 (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | |
AU765199B2 (en) | 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof | |
ES2321826T3 (en) | PEPTIC DERIVATIVES UNDERSTANDING THE TIAZEPIN GROUP FOR THE TREATMENT OF HYPERLIPIDEMIC DISEASES. | |
US6589959B1 (en) | Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt | |
RU2210574C2 (en) | Purified steroid-sulfamate compounds, estrone-sulfamates | |
FI93217C (en) | Process for the preparation of esters and amides of therapeutically active nucleoside derivatives | |
JP2008024712A (en) | Calcium salt of rosuvastatin : (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid, and, method for producing crystalline intermediates thereof | |
CA2014545C (en) | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
PL316994A1 (en) | Method of bonding e, p- or l-selection to sialyl-lewis x or sialyl-lewis a | |
JP2006519869A5 (en) | ||
JPH05155898A (en) | Amidinophenylalanine derivative and preparation thereof | |
JPH06509082A (en) | Method for producing derivatives of baccatin 3 and 10-deacetylbaccatin 3 | |
JP2006520822A5 (en) | ||
EP0480061B1 (en) | Hepatic disorder inhibitor | |
GB2025401A (en) | 5-fluoro ( uridine or 2 deoxy uridine derivatives | |
RU97114890A (en) | DERIVATIVES OF PROLINE, SUITABLE AS INHIBITORS OF HUMAN LEukocytes ELASTASIS | |
DK0475994T3 (en) | Macrolides for the treatment of reversible obstructive airway diseases | |
EP0304082A3 (en) | Positive resist patterns | |
JP2813450B2 (en) | Method for producing 3- (L-pyroglutamyl) -L-thiazolidine-4-carboxylic acid and derivatives thereof | |
Prugh et al. | Methyl 3-0-benzyl-2, 4, 6-trideoxy-6-iodo-α-d-erythro-hexopyranoside, a chiral synthon for the synthesis of inhibitors of HMG-CoA reductase | |
US5175320A (en) | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
Estevez et al. | Spirodiketopiperazines of mannofuranose: carbopeptoid α-amino acid esters at the anomeric position of mannofuranose | |
WO2009067225A4 (en) | Boceprevir derivatives for the treatment of hcv infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150303 |